Akebia Therapeutics Inc. buy Jefferies Financial Group Inc.
Start price
01.04.25
/
50%
€1.85
Target price
01.04.26
€5.54
Performance (%)
-44.81%
Price
05.03.26
€1.05
Summary
This prediction is currently active. Massive losses of -44.81% have been the result for the BUY prediction by Jefferies_Financial_. This prediction currently runs until 01.04.26. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | -6.020% | -6.020% |
| iShares Core DAX® | -5.868% | -2.496% |
| iShares Nasdaq 100 | 1.660% | 3.513% |
| iShares Nikkei 225® | -6.126% | 2.136% |
| iShares S&P 500 | 0.504% | 2.045% |
Comments by Jefferies_Financial_ for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat